Skip to main content

Table 1 The statistical analysis of NOV gene methylation pattern in different phases of CML

From: Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?

CpG position 40 47 68 102 111 113 124 126 147
 Me-CpG  Chronic 6/9 66.7% 2/9 22.2% 6/9 66.7% 4/9 44.4% 4/9 44.4% 6/9 66.7% 4/9 44.4% 6/9 66.7% 7/9 77.8%
P-value of Fisher’s exact test 0.7041 0.5908 0.1392 1.0000 1.0000 0.1157 0.7041 0.0403 0.0168
CpG position 153 163 179 199 211 224 246   Total
 Me-CpG  Chronic 8/9 88.9% 7/9 77.8% 4/9 44.4% 6/9 66.7% 6/9 66.7% 7/9 77.8% 4/8 50.0%   87/143 60.8%
P-value of Fisher’s exact test 0.0468 0.0074 0.6870 0.1157 0.0173 0.1251 1.0000   0.0000
CpG position 40 47 68 102 111 113 124 126 147
 Me-CpG  Accelerated 3/5 60.0% 4/5 80.0% 3/5 60.0% 3/5 60.0% 4/5 80.0% 2/5 40.0% 4/5 80.0% 5/5 100% 5/5 100%
P-value of Fisher’s exact test 1.0000 0.0058 0.6221 0.6424 0.3549 1.0000 0.1377 0.0032 0.0056
CpG position 153 163 179 199 211 224 246   Total
 Me-CpG  Accelerated 5/5 100% 5/5 100% 4/5 80.0% 1/5 20.0% 4/5 80.0% 4/5 80.0% 4/4 100%   60/79 75.9%
P-value of Fisher’s exact test 0.0447 0.0032 0.1282 1.0000 0.0195 0.3295 0.0932   0.0000
CpG position 40 47 68 102 111 113 124 126 147
 Me-CpG  Blastic 2/6 33.3% 4/6 66.7% 4/6 66.7% 4/6 66.7% 3/6 50.0% 4/6 66.7% 3/6 50.0% 5/6 83.3% 4/6 66.7%
P-value of Fisher’s exact test 0.3944 0.0138 0.3589 0.3944 1.0000 0.1735 0.6526 0.0132 0.1510
CpG position 153 163 179 199 211 224 246   Total
 Me-CpG  Blastic 6/6 100% 6/6 100% 4/6 66.7% 2/6 33.3% 4/6 66.7% 4/6 66.7% 5/6 83.3%   64/96 66.7%
P-value of Fisher’s exact test 0.0209 0.0013 0.1735 1.0000 0.0434 0.3944 0.1602   0.0000